



**Carmelo Rizzari
(Italy)**

Carmelo Rizzari is currently President-Elect of SIOPE Europe.

Carmelo has been involved in the field of paediatric leukaemias with a special interest for both traditional and innovative chemotherapy agents. He is currently running the Paediatric Haematology-Oncology Unit in Monza (within the frame of the University of Milano-Bicocca, Italy), which is one of the largest centres for the diagnosis and treatment of haematological malignancies in Italy.

Since the start of his career, Carmelo has been involved in the field of paediatric leukaemias with a special interest for both traditional and innovative chemotherapy agents.

He is also currently a member of the AIEOP National Board (Italian Association for Paediatric Haematology and Oncology) and Chairman of the AIEOP Clinical Pharmacology Committee, aiming to improve the knowledge and availability of innovative anti-cancer drugs in the country.

Carmelo is also a member of the national AIEOP scientific committees for first line and relapsed trials for ALL and AML and an active member of several scientific and steering international committees (e.g., AIEOP-BFM ALL trials, International BFM Study Group, ITCC, INTREALL). Within ITCC (Innovative Therapies for Children with Cancer), Carmelo served as member of the Quality and Accreditation Committee.

Carmelo is currently serving as the representative of the International BFM Study Group at ENPREMA (European Network for Paediatric Research at EMA), which aims to foster and integrate at the European level the research and innovation in different paediatric areas.

He is also currently national PI or Co-PI or local site PI for several national or international phase I and II Pharma sponsored or Academia driven studies involving innovative drugs for resistant/relapsed leukaemias and lymphomas.

Author or co-author of a large number of scientific publications, he has also actively participated in several international scientific meetings and disease-specific working groups.